


Vol. 8 No. 2 September 1991

ISSN 0790-9667

# IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE




**Modecate Abbreviated Prescribing Information. Indications:** Treatment of psychotic disorders. **Dosage – Modecate injection 25mg/ml.** Most patients are successfully maintained within the dosage range 12.5mg (0.5ml) every five weeks to 100mg (4ml) every two weeks. For full dosage information see Data Sheet. **Modecate concentrate injection 100mg/ml.** Adult patients found to require larger volumes of Modecate 25mg/ml may be transferred directly to the equivalent dose of Modecate concentrate on the basis that 1ml Modecate concentrate is equivalent to 4ml Modecate. **Contra-indications.** Patients with marked cerebral atherosclerosis, pheochromocytoma, renal or liver failure, or severe cardiac insufficiency. **Precautions.** Care should be taken in patients, particularly the elderly, who exhibit marked extrapyramidal reactions to oral phenothiazines. **Side effects.** Mainly extrapyramidal reactions. Drowsiness, lethargy, dryness of the mouth and mild hypotension may occur. **Product Licence No's and Prices.** **Modecate injection 25mg/ml.** PL 0034/5046. 10 x 1ml ampoule £25.20 **Modecate concentrate injection 100mg/ml.** PL 0034/0189. 10 x 0.5ml ampoule £49.99 5 x 1.0ml ampoule £48.86. Modecate is a Trade Mark of E. R. Squibb & Sons Ltd. Further information available from: Technical Services Department, E. R. Squibb & Sons Ltd., 141-149 Staines Road, Hounslow, Middlesex TW3 3JA. Tel: 01-572 7422.



# TRIED AND TRUSTED

19 years ago, E. R. Squibb & Sons helped lead a revolution in the community based treatment of schizophrenia when they introduced the depot neuroleptic concept. Since then worldwide clinical experience has confirmed the efficacy and safety of Modecate in over 800,000 patients. Modecate is now regarded by many psychiatrists as the standard depot neuroleptic.



Modecate is available in two strengths, allowing a wide dosage range with convenient injection volumes. Most patients can be controlled with an injection at intervals of 3 weeks or more. Modecate is less expensive than other depot neuroleptics when comparing equipotent doses.

1) Johnson DAW Br J Psychiat 1975; 126: 457-461.

E. R. Squibb & Sons Ltd., 141-149 Staines Road, Hounslow, Middlesex TW3 3JA. Tel: 01-572 7422.



# IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

Vol. 8 No. 2 September 1991 ISSN 0790-9667

16mm microfilm, 35mm microfilm, 105mm microfiche and article copies are available through **University Microfilms International**, 300 North Zeeb Road, Ann Arbor, Michigan 48106-1346, U.S.A.

Indexed and abstracted by **EXCERPTA MEDICA (EMBASE)**, **PSYCHOLOGICAL ABSTRACTS (PsycINFO, PsycLIT)**, **BIOLOGICAL ABSTRACTS/RRM (BIOSIS Previews)**; **Cumulative Index to Nursing and Allied Health Literature (CINAHL)**, **Linguistics and Language Behaviour Abstracts (LLBA)**, **Nutrition Abstracts and Reviews (CAB ABSTRACTS)**, **Referativnyi Zhurnal**, **Social Planning/Policy & Development Abstracts (SOPODA)**, and **Sociological Abstracts (SA)**.

## CONTENTS

**Front Cover description**..... 183

### EDITORIAL

**The role of the psychiatrist in child sexual abuse**..... 93  
*Noel McCune, Geraldine Walford*

### ORIGINAL PAPERS

**Naloxone: lack of effect of a very low dose on fluid intake and activity in rats**..... 100  
*Robert Bell, Sheree Davis*

**The role of memory on the dentally anxious patient's response to dental treatment**..... 110  
*Ruth Freeman*

**Public attitudes to depression: a national survey**..... 116  
*Patrick McKeon, Siobhan Carrick*

**Female prison transfers to the Central Mental Hospital, a Special Hospital (1983-1988)**..... 122  
*Art O'Connor, Helen O'Neill*

**Post-traumatic stress disorder in women who were victims of childhood sexual abuse**..... 124  
*Kevin O'Neill, Kamal Gupta*

**Motivation towards learning and behaviour deviance in eight to eleven year old children attending an urban primary school**..... 128  
*Sylvia O'Regan, Michael Fitzgerald, Anthony Kinsella*

### CLINICAL AND BRIEF REPORTS

**Persistent neuroleptic-related hypersomnia: two case reports**..... 130  
*Riadh T Abed, D Bhalla*

**Lack of effect of electroconvulsive therapy on CSF peptide concentrations in schizophrenic patients**..... 132  
*Stephen J. Cooper, C F Johnston, David J King*

**Copgras syndrome associated with a frontal lobe tumour**.. 135  
*Shiban K Durani, Rodney Ford, S H A Sajjad*

**Unilateral auditory hallucinations - a case report**..... 136  
*Asaf M Khan, Vallepur H R Krishnan*

**Psychiatrists and family therapy: impressions at the interface of ideology and practice**..... 138  
*Declan Finnian Sheerin*

### REVIEW ARTICLES

**Psychometrics in assessing hepatic encephalopathy - a brief review**..... 144  
*Mark G Davies, Michael J Rowan, John Feely*

**To reminisce or not to reminisce**..... 147

**Juvenile Huntington's Disease**..... 149  
*Brian O'Shea, Jane Falvey*

### PERSPECTIVES

**Bio-psycho-social interactions in anxiety and panic disorders: a speculative perspective**..... 154  
*Malcolm Lader*

**Comments on lithium treatment**..... 160  
*Mogens Schou*

### PRACTICE REVIEW

**Antidepressants: uses and attitudes among consultant psychiatrists - a questionnaire study**..... 167  
*Brian O'Shea*

### HISTORICAL

**Wernicke**..... 172  
*Caoimhghin S Breathnach*

### LETTERS TO THE EDITOR

**Pemoline and neuroleptic-induced side effects**..... 174  
*Philip L Huckle, Roger Thomas*

**Irish general practice and clinical psychology**..... 174  
*Paul E McQuaid, Declan Aherne (Author's reply)*

### BOOK REVIEWS

**Royal Academy of Medicine in Ireland, Psychiatry Section Meetings 1991/1992**..... 108

**Addendum to Guidelines for authors**..... 127

**Index to advertisers**..... 143

**John Dunne Medal winner**..... 170

### EDITORIAL BOARD:

**Editor:** Mark Hartman (Dublin).

**Deputy Editor:** Roy McClelland (Belfast).

**Associate Editors:** Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Ethna O'Gorman, (Belfast), Brian O'Shea (Dublin).

**Assistant Editors:** Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Timothy Dinan (Dublin), David King (Belfast), Brian Leonard (Galway), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary).

**Statistical editor:** Leslie Daly (Dublin).

**Managing Editor:** Aidan McGennis (Dublin).

Journal listed in **Ulrich's International Periodicals Directory (Bowker's International Serials Database)**, **EBSCO's Selected Periodicals for the Medical and Health Sciences**, **EBSCO's Librarians' Handbook**.  
PRINTING AND TYPESETTING: Turner Print Group, Longford and Dublin. Tel: Longford (043) 46275; Dublin (01) 765032. COVER DESIGN: Martina Leonard.  
ADVERTISERS: Boots, Bristol-Myers Squibb, Ciba-Geigy, Delandale, Duphar, Eli Lilly (Dista), E Merck, Fisons (CP Pharm), Hoechst, Janssen, Lundbeck, Merrell Dow, Norgine, Organon, Reckitt & Colman, Rhone-Poulenc Rorer, Roche, Roussel, SmithKline Beecham, Upjohn, Wellcome.  
CIRCULATION: 3,100 to 54 countries. This journal participates in the World Health Organization project to improve the distribution of scientific materials on mental health. FREQUENCY: Twice yearly (May and November).  
SUBSCRIPTION RATES (Annual): £42 Europe, \$84 outside Europe, including postage.  
ADDRESS: All submissions and correspondence to the Editor, Irish Journal of Psychological Medicine, St. Brendan's Hospital, Rathdown Road, Dublin 7, Ireland. Telephone: (088) 578406; international: (353 88) 578406. Fax: (01) 280 0504; international: (353 1) 280 0504. PUBLISHER: Irish Institute of Psychological Medicine Ltd.  
Publishing of any material, including advertisements, does not necessarily imply endorsement by the Irish Institute or Journal of Psychological Medicine.



moclobemide

# MANERIX

## New Horizons in the Treatment of Depression

### The First RIMA\*

## MANERIX

\*The first R.I.M.A. antidepressant  
**R**eversible **I**nhibition of **M**ao-**A**

#### Brief Prescribing Information

**Indication:** Moderate or severe depression. **Dosage:** Adults Usual starting dose 300mg daily, range 150 - 600mg daily. Elderly as adults. Children Not recommended. **Contra-indications:** Known hypersensitivity to Manerix, acute confusional states. Do not co-administer with pethidine. **Precautions:** Monitor suicidal patients closely initially. Precipitation of manic episodes possible in bipolar disorders. Restlessness or agitation possible in depression. No experience in schizophrenic disorders. Theoretical risk of hypertensive reaction in thyrotoxicosis or phaeochromocytoma. Use with caution in epilepsy. Although performance of skilled tasks not generally affected monitor initially. Safety in pregnancy not established. Depressive patients with excitation or agitation as the predominant clinical feature should either not be treated with Manerix or only in combination with a sedative (e.g. a benzodiazepine, for not more than two to three weeks). **Dietary precautions:** Despite reduced risk of food interactions due to reversible nature of inhibition and selectivity for MAO-A, hypertensives should avoid eating more than 100g mature cheese. **Drug Interactions:** Manerix potentiates ibuprofen and opiates, and may alter dose requirements of morphine and fentanyl. Reduce Manerix dose by half if given with cimetidine. Possible potentiation and prolongation of effects of systemic sympathomimetics. Insufficient data on use with 5-HT uptake inhibitors/analogs. **Side-effects and adverse reactions:** Transient sleep disturbance, dizziness, nausea and headache. Reversible confusional states. Possible anticholinergic-like effects. Immediate reporting to NDAB required. **Overdosage:** increased agitation, aggressiveness and behavioural changes. Maintain vital functions. Further Information: Use under specialist medical supervision. **Pharmaceutical Precautions:** Store in dry place. **Legal Category:** Restricted to sale or supply on prescription. **Presentation:** 150mg tabs x 30. **Product Authorisation Number:** PA 50/81/2 (150mg). **Authorisation Holder:** Roche Products Ltd., PO Box 8, Welwyn Garden City, Herts, AL7 3AY. **Distributor:** Roche Pharmaceuticals (Ireland) Ltd, Unit 21, Beechwood Close, Boghall Road, Bray, County Wicklow. **Full prescribing information available on request.**

#### References

1. Versiani, M. et al: A double-blind comparative trial of moclobemide vs imipramine and placebo in major depressive episodes. Br J Psychiatry Vol 55, Suppl 6, p72-77 (1989).
2. Lecrubier, Y.: Efficacy of reversible inhibitors of MAO-A in various forms of depression. Acta Psychiatrica Scand. Suppl. 360 Vol 82 p18-23 (1990).
3. McClelland, G.: Data on file. Roche Products GCR 144785.
4. Versiani, M. et al: Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatrica Scand. Suppl. 360, Vol 82, p24-28 (1990).
5. Cassidy and Henry: Fatal toxicity of Antidepressant Drugs in Overdose. BMJ Vol 295 6605 p1021-1024 (1987).
6. Chapter 2 Myler's Side Effects of Drugs 11th Edition Ed. MNG Dukes.
7. Hetzel, W.: Safety of moclobemide in Overdose for Suicidal Attempts. Submitted for publication in Psychopharmacology.
8. Monti, JM: Effect of a Reversible Monoamine Oxidase-A Inhibitor (Moclobemide) on Sleep of Depressed Patients. Br J Psychiatry Vol 155, Suppl 6, p61-65 (1989).
9. Hindmarsh, I. & Kerr J.: The Behavioural Toxicity of Antidepressants with particular reference to Moclobemide.
10. Baumhackl, U. et al: Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-111) - An Austrian Double-Blind, Multicentre Study. Br J Psychiatry Vol 155 Suppl 6 p78-83 (1989).



a leader in CNS research

MANERIX is a Trade Mark